more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Scancell, Neuphoria Agree to All-Share Merger

  ()
Neuphoria Therapeutics Inc. (NEUP:NASDAQ) and Scancell Holdings Plc (SCNLF:OTC; SCLP:AIM) agreed to an all-share merger, listing the combined company on Nasdaq while funding a Phase 3 melanoma trial.
Tags: Biotechnology / Pharmaceuticals

Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing

  ()
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

  ()
Scancell advances its iSCIB1+ melanoma program toward Phase 3 after agreeing to an all-share merger that brings Nasdaq access and up to $89 million in new financing.
Tags: Biotechnology / Pharmaceuticals

Smith & Nephew Expands Wound Care Portfolio in $22B Market

  ()
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

FDA Approves First Ophthalmic Treatment for Wet AMD, Leading Wainwright to Triple Price Target

  ()
Outlook Therapeutics Inc.'s (OTLK:NASDAQ) LYTENAVA received FDA approval as the first ophthalmic bevacizumab for wet AMD, with U.S. launch targeted by year-end 2026
Tags: Biotechnology / Pharmaceuticals

Novocure Posts Record Q2 Revenue of US$183.6M

  ()
Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.
Tags: Biotechnology / Pharmaceuticals

Novocure Hits Record Revenue and Raises 2026 Outlook

  ()
Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Ashok Kumar Says Commercial Runway Supports Outlook for Health Co.

Research Report
  ()
Visible commercial conversion and improving cash use through the third-quarter report would strengthen the base case and support confidence in the rating and target.
Tags: Biotechnology / Pharmaceuticals

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Research Report
  ()
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."
Tags: Biotechnology / Pharmaceuticals

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

  ()
PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals signed a deal worth up to US$330 million to commercialize D-PLEX100, an infection-prevention drug, in the U.S. and Canada.
Tags: Biotechnology / Pharmaceuticals

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

  ()
PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

  ()
BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.
Tags: Biotechnology / Pharmaceuticals

BioMarin Advances VOXZOGO Toward Full FDA Approval

  ()
BioMarin submits sNDA for traditional VOXZOGO approval in achondroplasia with a Feb 2027 PDUFA date backed by extensive long-term data and an expanding skeletal dysplasia market opportunity.
Tags: Biotechnology / Pharmaceuticals

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

  ()
Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is selling its Phase 3 antibiotic to Biossil for up to US$104.5 million in milestones, refocusing on its oncology drug ivonescimab.
Tags: Biotechnology / Pharmaceuticals

Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target

  ()
Roth, Chardan Capital, and H.C. Wainwright have all issued "Buy" ratings on Coya Therapeutics Inc. (COYA:NASDAQ) in 2026. Read on to find out why analysts are intrigued.
Tags: Biotechnology / Pharmaceuticals

Houston ALS Biotech Coya Eyes 2028 Approval Path

  ()
Coya Therapeutics advances COYA 302 for ALS with strong analyst support and a key 2027 readout ahead. Discover the catalysts and industry trends driving this Houston biotech.
Tags: Biotechnology / Pharmaceuticals

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Tags: Biotechnology / Pharmaceuticals

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

  ()
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.
Tags: Biotechnology / Pharmaceuticals

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
Tags: Biotechnology / Pharmaceuticals

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Research Report
  ()
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.
Tags: Biotechnology / Pharmaceuticals

Air Force Bases Renew Their Contracts With Cleantech Pioneer

  ()
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

  ()
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?

  ()
Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.
Tags: Biotechnology / Pharmaceuticals

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

  ()
Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.
Tags: Biotechnology / Pharmaceuticals

French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Research Report
  ()
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 26 to 50 of 127 Prev Next